| Finch Therapeutics Fetches $90M to Advance Microbiome Drug Pipeline | Frank Vinluan | 09/17/20 | Boston |
| Roche Gut Disease Drug Produces Mixed Results in Late-Stage Trials | Sarah de Crescenzo | 08/11/20 | National |
| Applied Molecular Plots IPO to Back Transport of Biologic Drugs to Gut | Frank Vinluan | 05/20/20 | San Francisco |
| From Overseas, Legend Biotech and Calliditas Therapeutics Eye the Nasdaq | Frank Vinluan | 05/15/20 | New York |
| Why 2020 Is Pivotal for Microbiome Drug R&D (Or Maybe 2021, Given COVID-19) | Frank Vinluan | 04/22/20 | National |
| FDA Approves Bristol Myers MS Drug, But Pandemic Will Delay Launch | Frank Vinluan | 03/26/20 | New York |
| PanTheryx Lands $50M to Use “First Milk” to Target Gut Microbiome | Frank Vinluan | 06/26/19 | Boulder/Denver |
| With Yale Tech and $12M, Artizan Aims for Root Cause of Gut Disease | Frank Vinluan | 06/10/19 | Boston |
| Celgene Submits MS Drug for Approval in Europe, FDA Filing on Track | Frank Vinluan | 03/11/19 | New York |
| Arena’s Comeback Continues with $800M Deal for Lung Disease Drug | Frank Vinluan | 11/15/18 | San Diego |
| Synthorx Files for IPO to Advance Enhanced Cytokine Drugs | Sarah de Crescenzo | 11/14/18 | San Diego |
| Sangamo Bags TxCell, and a Next-Gen Cell Therapy Tech, for $84M | Ben Fidler | 07/23/18 | San Francisco |
| The Revolution in Inflammation Drug Development | Gary Glick | 05/15/18 | Boston |
| Arena Pharma’s Revamp Gains Traction With New Data For GI Drug | Ben Fidler | 03/20/18 | San Diego |
| FDA Refuses to Review Celgene’s MS Drug, Says File “Insufficient” | Frank Vinluan | 02/27/18 | New York |
| Celularity Raises $250M to Make Stem Cell Treatments for Cancer & More | Frank Vinluan | 02/15/18 | New York |
| Theravance Snares $100M From Janssen in Stomach Drug Deal | Frank Vinluan | 02/07/18 | San Francisco |
| Landos Joins Garabedian’s Bio Startup Accelerator Xontogeny, Gets $10M | Frank Vinluan | 09/21/17 | Boston |
| SetPoint Nabs $30M For More Tests of Bioelectric Device as RA Therapy | Frank Vinluan | 08/28/17 | San Francisco |
| Protagonist, Janssen Ink Development Deal for Crohn’s Disease Drug | Frank Vinluan | 05/30/17 | San Francisco |
| Early Data for Celgene’s Oral Crohn’s Drug Gets Mixed Reaction | Ben Fidler | 10/17/16 | New York |
| Bio Roundup: Theranos Cuts, Alnylam Stops, Nobel Eats Its Own & More | Alex Lash | 10/07/16 | National |
| Biotech Roundup: CRISPR’s 3rd IPO, Gender Diversity, Buyouts & More | Ben Fidler | 09/16/16 | National |
| Sofinnova, Atlas Put $35M Into Delinia to Tackle Autoimmune Diseases | Ben Fidler | 09/14/16 | Boston |
| Celgene Touts Data From Early Study of Oral GI Drug | Ben Fidler | 09/12/16 | Boston |
| Second Genome Replaces DiLaura as CEO, Brings Series B to $51M | David Holley | 07/13/16 | San Francisco |
| Probing Gut Microbiome, Second Genome Nabs $43M To Push Colitis Drug | Alex Lash | 04/20/16 | San Francisco |
| New PureTech Startup Commense Aims to Protect Babies From Disease | Ben Fidler | 03/31/16 | Boston |
| Synlogic Nabs $40M, Prepares To Put Modified Microbes Into Patients | Ben Fidler | 02/17/16 | Boston |
| Seres Inks Nestlé As Potential $2B Partner; Key Microbiome Data Soon | Alex Lash | 01/11/16 | Boston |
